MedTrace Logo

Equol Supplementation on Blood Pressure and Vascular Function

NCT02515682 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 207

Last updated 2015-08-05

No results posted yet for this study

Summary

We propose to perform a 24-week randomized, double-blind a placebo-controlled trial among 207 non-equol producing postmenopausal women with prehypertension to examine the effectiveness of equol (10mg and 20mg/d) on 24h ambulatory blood pressure, vascular function and other cardiovascular risks (lipid profile, glycemic control and inflammatory biomarkers) and explore the optimal dosage of equol.

Conditions

Interventions

DIETARY_SUPPLEMENT

High equol group

Participants will be give natural S-equol 20mg/d for 24 weeks.

DIETARY_SUPPLEMENT

Low equol group

Participants will be give natural S-equol 10mg/d for 24 weeks.

DIETARY_SUPPLEMENT

Placebo

Participants will be give placebo for 24 weeks.

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
48 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2018-07-31
Completion
2018-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02515682 on ClinicalTrials.gov